



Dkt. 0575/55424-A-PCT-US/JPW/JM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
AUG 23 2001  
TECH CENTER 1600/2900

Applicants : Ann Marie Schmidt, et al.  
Serial No. : 09/689,469  
Filed : October 12, 2000  
For : A METHOD FOR INHIBITING TUMOR INVASION OR  
SPREADING IN A SUBJECT

1185 Avenue of the Americas  
New York, New York 10036  
August 9, 2001

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are listed on the PTO-1449 form attached hereto as **Exhibit A**.

1. WO98/22138 A1 (The Trustees Of Columbia University In The City Of New York) 28 May 1998;
2. Hori et al. 'The Receptor for Advanced Glycation Endproducts: Implications for the Development of Diabetic Vascular Disease. Fundam. Clin. Cardiol.' In: The Endothelium in Clinical Practice. January 1997, Chapter 11, pages 311-329;
3. Chen et al. Amyloid-beta Peptide- Receptor for Advanced

Applicants: Ann Marie Schmidt, et al.  
U.S. Serial No.: 09/689,469  
Filed: October 12, 2000  
Page 2

- Glycation    Endproduct    Interaction    Elicits    Neuronal  
Expression of Macrophage-Colony Stimulating Factor: A  
Proinflammatory Pathway in Alzheimer Disease. Proc. Natl.  
Acad. Sci. 13 May 1997, Vol. 94, No. 10, pages 5296-5301;
4. Schmidt et al. V-domain of Receptor for Advanced Glycation  
Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target  
for Therapy of Diabetic Complications. Circulation. 21  
October 1997, Vol. 96, No. 8 Suppl., page I37;
  5. Hori et al. The Receptor for Advanced Glycation Endproducts  
(RAGE) Is A Cell Surface Receptor for Amphotericin in the  
Developing Central Nervous System (CNS) to Promote Neurite  
Outgrowth. FASEB J. 1995, Vol. 9, No. 3, page A382;
  6. International Search Report of International Application  
No. PCT/US99/08427, dated July 29, 1999;
  7. Morser et al., U.S. Patent No. 5,864,018, filing date April  
16, 1996 (**Exhibit B**);
  8. Morser et al. PCT International Application No.  
PCT/EP97/01832, filed 11 April 1997, published October 23,  
1997, Publication No. WO 97/39121, Advanced Glycation  
Endproduct Receptor Peptides and Uses Thereof (**Exhibit C**).
  9. Morser et al. PCT International Application No.  
PCT/EP97/01834, filed April 11, 1997, published October 23,  
1997; Publication No. WO 97/39125, Antibodies Against the  
Advanced Glycation Endproduct Receptor and Uses Thereof

Applicants: Ann Marie Schmidt, et al.  
U.S. Serial No.: 09/689,469  
Filed: October 12, 2000  
Page 3

(**Exhibit D**).

10. Park, L., et al. (1998) "Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE)" Nature Medicine, 4:1025-1031 (**Exhibit E**).
11. Vlassara, H., et al. (1995) "Identification of Galectin-2 as a high affinity binding protein for Advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex" Molecular Medicine, 1:634-646 (**Exhibit F**).
12. Vlassara et al., US Patent 5,585,344 (**Exhibit G**).
13. Yan S-D, Chen X, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern DM, Schmidt A-M: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. *Nature* 1996;382:685-691 (**Exhibit H**).

The above-listed documents numbered 1-6 were originally submitted to the U.S. Patent and Trademark Office in connection with parent application U.S. Serial No. 09/062,365 from which the present application claims priority under 35 U.S.C. §120, therefore, copies of these documents are not enclosed herewith. Copies of references 7-13 are attached hereto as **Exhibits B-H**. Applicants request that the Examiner make these documents of record.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned

Applicants: Ann Marie Schmidt, et al.  
U.S. Serial No.: 09/689,469  
Filed: October 12, 2000  
Page 4

attorney invites the Examiner to telephone at the number provided below.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required in connection with the filing of this Information Disclosure Statement, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Jane M. Love

I hereby certify that this paper is being deposited this date with the U.S. Postal Service as first class mail addressed to: Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Jane M. Love 8/9/01  
Jane M. Love Date  
Reg. No. 42,812

John P. White  
Registration No. 28,678  
Jane M. Love  
Registration No. 42,812  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400